RxDoctor Payments Data

Alayn Govea, MD

Interventional Cardiology · Lakewood, CANPI 1972997104

Payments from drug & device makers

$23,432in general payments, 2019–2025

Across 159 payments — averaging $147.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$12K
  • Abbott$6K
  • Boston Scientific$1K
  • Abiomed$963
  • Edwards Lifesciences$919
  • Shockwave Medical, Inc$867
  • plus $2K from 17 others
$150in research payments, 2019–2025

Across 2 payments — averaging $75.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$150

What the payments were for

  • Grants$15,90068%
  • Travel & lodging$3501%
  • Food & beverage$7,16731%
  • Education$150%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,432 in reported general payments places this provider in the 65th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$104,254
Medicare patients
208
Services billed
894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban82$94,333
EntrestoSacubitril/Valsartan36$34,471
Repatha SureclickEvolocumab36$19,242
JardianceEmpagliflozin17$12,488
FarxigaDapagliflozin Propanediol15$11,839
Metoprolol Succinate141$1,845
Atorvastatin Calcium159$1,447
Carvedilol157$1,121
Rosuvastatin Calcium23$636
ClopidogrelClopidogrel Bisulfate56$620
Isosorbide Mononitrate ErIsosorbide Mononitrate38$608
Bumetanide14$497
Amiodarone Hcl17$449
Amlodipine Besylate134$341
Losartan Potassium46$309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$114$34,47136 claims
Boehringer IngelheimJardiance$186$12,48817 claims
AstraZenecaFarxiga$250$11,83915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Lakewood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →